Literature DB >> 542916

Isocyanate asthma: respiratory symptoms due to 1,5-naphthylene di-isocyanate.

M G Harries, P S Burge, M Samson, A J Taylor, J Pepys.   

Abstract

Occupationally related asthma developing in three patients due specifically to exposure to 1,5-naphthylene di-isocyanate (NDI), a hot curing agent used in manufacturing rubber, has been confirmed for the first time using bronchial provocation testing. This substance has been thought to be safer than toluene di-isocyanate (TDI) and diphenylmethane di-isocyanate (MDI) because of its relatively high melting point (120 degrees C). Each patient worked in the same factory and the circumstances of exposure were similar. Provocation testing was also performed with TDI in concentrations up to 0.018 parts per million (ppm) and MDI in concentrations up to 0.02 ppm, to which the patients had been exposed in the past, but no reactions were elicited. None of the patients had increased bronchial reactivity judged by histamine lability and exercise testing. Each patient was advised to give up his job, but two of the three could not find alternative employment and remained exposed. Three-year follow-up shows that airways narrowing has persisted in those who have remained exposed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 542916      PMCID: PMC471193          DOI: 10.1136/thx.34.6.762

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  METHANE DIISOCYANATE: A RESPIRATORY HAZARD?

Authors:  E O LONGLEY
Journal:  Arch Environ Health       Date:  1964-06

2.  [Clinical and experimental study of some cases of poisoning by desmodur T (1-2-4 and 1-2-6 di-isocyanates of toluene)].

Authors:  S FUCHS; P VALADE
Journal:  Arch Mal Prof       Date:  1951

3.  Toluene di-isocyanate-induced asthma. II. Inhalation challenge tests and bronchial reactivity studies.

Authors:  I M O'Brien; A J Newman-Taylor; P S Burge; M G Harries; I W Fawcett; J Pepys
Journal:  Clin Allergy       Date:  1979-01

4.  Isocyanate asthma: respiratory symptoms caused by diphenyl-methane di-isocyanate.

Authors:  A R Tanser; M P Bourke; A G Blandford
Journal:  Thorax       Date:  1973-09       Impact factor: 9.139

5.  Peak flow rate records in the diagnosis of occupational asthma due to isocyanates.

Authors:  P S Burge; I M O'Brien; M G Harries
Journal:  Thorax       Date:  1979-06       Impact factor: 9.139

6.  The in vitro effect of toluene diisocyanate on lymphocyte cyclic adenosine monophosphate production by isoproterenol, prostaglandin, and histamine: a possible mode of action.

Authors:  R J Davies; B T Butcher; C E O'Neil; J E Salvaggio
Journal:  J Allergy Clin Immunol       Date:  1977-10       Impact factor: 10.793

7.  Toluene diisocyanate (TDI) pulmonary disease: immunologic and inhalation challenge studies.

Authors:  B T Butcher; J E Salvaggio; H Weill; M M Ziskind
Journal:  J Allergy Clin Immunol       Date:  1976-07       Impact factor: 10.793

  7 in total
  5 in total

1.  Biological monitoring of exposure to 1,5-naphthalene diisocyanate and 4,4'-methylenediphenyl diisocyanate.

Authors:  C J Sennbro; C H Lindh; C Mattsson; B A G Jönsson; H Tinnerberg
Journal:  Int Arch Occup Environ Health       Date:  2006-02-28       Impact factor: 3.015

2.  Occupational asthma and extrinsic alveolitis due to isocyanates: current status and perspectives.

Authors:  O Vandenplas; J L Malo; M Saetta; C E Mapp; L M Fabbri
Journal:  Br J Ind Med       Date:  1993-03

Review 3.  Challenge procedures in occupational asthma.

Authors:  J Pepys
Journal:  Bull N Y Acad Med       Date:  1981-09

4.  Amines: possible causative agents in the development of bronchial hyperreactivity in workers manufacturing polyurethanes from isocyanates.

Authors:  L Belin; U Wass; G Audunsson; L Mathiasson
Journal:  Br J Ind Med       Date:  1983-08

5.  Bronchial asthma and COPD due to irritants in the workplace - an evidence-based approach.

Authors:  Xaver Baur; Prudence Bakehe; Henning Vellguth
Journal:  J Occup Med Toxicol       Date:  2012-09-26       Impact factor: 2.646

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.